DRAD vs. HSDT, NDRA, NUWE, TIVC, BSGM, TCON, SNGX, ARTL, PEAR, and ENSC
Should you be buying Digirad stock or one of its competitors? The main competitors of Digirad include Helius Medical Technologies (HSDT), ENDRA Life Sciences (NDRA), Nuwellis (NUWE), Tivic Health Systems (TIVC), BioSig Technologies (BSGM), TRACON Pharmaceuticals (TCON), Soligenix (SNGX), Artelo Biosciences (ARTL), Pear Therapeutics (PEAR), and Ensysce Biosciences (ENSC). These companies are all part of the "medical" sector.
Helius Medical Technologies (NASDAQ:HSDT) and Digirad (NASDAQ:DRAD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.
Helius Medical Technologies has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Digirad has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500.
Digirad has higher revenue and earnings than Helius Medical Technologies. Digirad is trading at a lower price-to-earnings ratio than Helius Medical Technologies, indicating that it is currently the more affordable of the two stocks.
18.6% of Helius Medical Technologies shares are held by institutional investors. Comparatively, 11.4% of Digirad shares are held by institutional investors. 7.3% of Helius Medical Technologies shares are held by insiders. Comparatively, 12.5% of Digirad shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Digirad has a net margin of -5.32% compared to Digirad's net margin of -1,374.22%. Helius Medical Technologies' return on equity of -3.75% beat Digirad's return on equity.
Helius Medical Technologies presently has a consensus price target of $54.50, suggesting a potential upside of 1,948.87%. Given Digirad's higher possible upside, research analysts clearly believe Helius Medical Technologies is more favorable than Digirad.
In the previous week, Digirad's average media sentiment score of 0.00 equaled Helius Medical Technologies'average media sentiment score.
Digirad received 298 more outperform votes than Helius Medical Technologies when rated by MarketBeat users. Likewise, 70.35% of users gave Digirad an outperform vote while only 57.14% of users gave Helius Medical Technologies an outperform vote.
Summary
Digirad beats Helius Medical Technologies on 9 of the 15 factors compared between the two stocks.
Get Digirad News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRAD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
